Glycopeptide Antibiotics Market Size to Exceed USD 4,317.2 Mn by 2032

The Glycopeptide Antibiotics Market, estimated at USD 3,236.9 Mn in 2025, is expected to exhibit a CAGR of 4.2% and reach USD 4,317.2 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Key trends in the market include increasing prevalence and incidences of cancer. For instance, data published in November 2025, on Canada.ca, stated that in 2025, an estimated 229,200 Canadians were diagnosed with cancer.

Global Glycopeptide Antibiotics Market – Impact of Coronavirus (COVID-19) Pandemic

Governments of various countries are focusing on initiatives to fight against the COVID-19 pandemic and stop the spread of the coronavirus infection by implementing various measures. Countries such as India, the U.A.E., the U.K., and others have implemented some measures and guidelines to reduce the spread of COVID-19. The government of India announced a nationwide lockdown in March 2025, wherein all public facilities, public spaces, educational institutes, state borders, religious places, and others were physically shut to curb the spread of coronavirus in the country.Furthermore, the Indian government started focusing on improving its healthcare infrastructure and making vaccination facilities available to all citizens of the country. According to an article published by the Frontiers in Public Health Journal in February 2025, the government of Nepal had set up 36 COVID-19 dedicated hospitals to provide healthcare for mild, moderate, and severe COVID-19 cases in Nepal. The government of Nepal also designated Sukraraj Infectious and Tropical Disease Hospital (SITDH), Patan Hospital, and the Armed Police Forces Hospital in Kathmandu as the primary hospitals for COVID treatment. According to data published by the Organization for Economic Co-operation and Development (OECD) in November 2025, people found guilty of not following any of the quarantine and curfew measures were heavily penalized in Saudi Arabia, Jordan, and the U.A.E

Browse 22 Market Data Tables and 18 Figures spread through 154 Pages and in-depth TOC on “Global Glycopeptide Antibiotics Market”- Forecast to 2032, global Glycopeptide Antibiotics Market, by Drug (Vancocin, Orbactiv, Dalvance, Kimyrsa, and Others), by Disease Indication (Clostridium difficile-associated Diarrhea, Endocarditis, Skin Structure Infections, and Others), by Distribution channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/glycopeptide-antibiotics-market-5455

Moreover, an increase in the number of clinical studies is expected to drive the market growth over the forecast period. For instance, acoording to data published on November 2025 on ClinicalTrials.gov, as of March 2025, ClinicalTrials.gov listed 434,253 studies with locations in 221 countries.

Key Takeaways of the Global Glycopeptide Antibiotics Market:

• Global glycopeptide antibiotics market is expected to exhibit a CAGR of 4.2% during the forecast period due to increasing product approvals. For instance, the U.S. Food and Drug Administration (FDA) approved Kimyrsa (oritavancin; Melinta Therapeutics) in March 2025 for the treatment of adults with Acute Bacterial Skin and Skin Structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms.
• Among region, Asia Pacific is estimated to exhibit the highest CAGR in the global glycopeptide antibiotics market over the forecast period, owing to increasing clinical trial operations in the region. For instance, a 2025 National Institutes of Health (NIH) analysis found that a total of 125,918 registered clinical trials were carried out across Asia. China (21.1%), Japan (30.8%), and India (14.3%) also hosted trials in Asia.
• Major players operating in the global glycopeptide antibiotics market are ANI Pharmaceuticals, Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc., Melinta Therapeutics, Inc, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Janssen Global Services, LLC, Bristol-Myers Squibb Company, and GlaxoSmithKline plc.